AZ/Merck’s Lynparza approved by SMC to treat advanced prostate cancer in Scotland
Up to 20% of prostate cancer cases are classified as castration-resistant
Read More
Tag: metastatic castration-resistant prostate cancer
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
